parsaclisib
Parsaclisib is a drug used to treat Lymphoma, Advanced Malignancies, B-Cell Malignancies, and other conditions. Parsaclisib is being actively studied in 20 studies and prior, has been studied in 5.
Top Sponsors | Top Sites | Top Investigators |
---|---|---|
Incyte Corporation | Hospital Universitario Virgen Del Rocio | John Reneau |
Incyte Biosciences Japan GK | Hospital Clinico Universitario de Salamanca | Junning Cao, MD |
Fudan University | Tel Aviv Sourasky Medical Center | Yanyan Liu |
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
F
Not yet recruiting
- PI3Kδ Inhibitor
- +3 more
- Parsaclisib
- CHOP
- (no location specified)
2022-02-10
Feb 10, 2022H
Not yet recruiting
- Peripheral T-Cell Lymphoma
- Parsaclisib
- Chidamide
- Zhengzhou, Henan, ChinaHenan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
2021-12-26
Dec 26, 2021I
Not yet recruiting
- Follicular Lymphoma ( FL)
- Marginal Zone Lymphoma (MZL)
- parsaclisib
- +2 more
- (no location specified)
2022-02-07
Feb 7, 2022O
Recruiting
- Recurrent Anaplastic Large Cell Lymphoma
- +8 more
- Parsaclisib
- Romidepsin
- Columbus, OhioOhio State University Comprehensive Cancer Center
2021-10-07
Oct 7, 2021I
Recruiting
- B-Cell Malignancies
- Parsaclisib
- +3 more
- Birmingham, Alabama
- +28 more
2022-03-30
Mar 30, 2022U
Withdrawn
- Breast Cancer
- +3 more
- Parsaclisib
- (no location specified)
2020-11-02
Nov 2, 2020I
Active, not recruiting
- Advanced Malignancies
- parsaclisib
- Tustin, California
- +3 more
2022-03-14
Mar 14, 2022I
Completed
- Advanced Malignancies
- parsaclisib
- Rialto, California
- +4 more
2022-03-28
Mar 28, 2022I
Not yet recruiting
- Mantle Cell Lymphoma
- parsaclisib
- +3 more
- (no location specified)
2022-02-14
Feb 14, 2022I
Active, not recruiting
- MPN (Myeloproliferative Neoplasms)
- Parsaclisib
- Ruxolitinib
- Birmingham, Alabama
- +38 more
2022-04-05
Apr 5, 2022I
Completed
- Primary Sjögren's Syndrome
- Parsaclisib
- Miami, Florida
- +3 more
2021-08-11
Aug 11, 2021I
Active, not recruiting
- Lymphoma
- Parsaclisib
- Aichi, Japan
- +5 more
2022-01-24
Jan 24, 2022I
Recruiting
- Non Hodgkins Lymphoma
- Diffuse Large B-cell Lymphoma
- tafasitamab
- +3 more
- Aichi, Japan
- +4 more
2022-01-24
Jan 24, 2022M
Recruiting
- Ann Arbor Stage II Diffuse Large B-Cell Lymphoma
- +13 more
- Cyclophosphamide
- +6 more
- Scottsdale, Arizona
- +2 more
2021-08-19
Aug 19, 2021I
Recruiting
- Chronic Lymphocytic Leukemia
- Non Hodgkin Lymphoma
- tafasitamab
- parsaclisib
- Birmingham, Alabama
- +48 more
2022-03-30
Mar 30, 2022I
Completed
- B-Cell Malignancies
- Parsaclisib
- +5 more
- Birmingham, Alabama
- +6 more
2021-05-03
May 3, 2021I
Active, not recruiting
- Autoimmune Hemolytic Anemia
- Parsaclisib
- Washington, District of Columbia
- +12 more
2021-12-14
Dec 14, 2021I
Withdrawn
- Pemphigus Vulgaris
- Parsaclisib
- (no location specified)
2019-09-11
Sep 11, 2019I
Completed
- Lymphoma
- Parsaclisib
- +2 more
- Gilbert, Arizona
- +20 more
2021-12-01
Dec 1, 2021I
Recruiting
- Lymphoma
- parsaclisib
- Anjo, Japan
- +29 more
2022-02-23
Feb 23, 2022I
Active, not recruiting
- B-cell Lymphoma
- Parsaclisib
- +3 more
- Tucson, Arizona
- +20 more
2022-03-29
Mar 29, 2022I
Recruiting
- Myelofibrosis
- +3 more
- parsaclisib
- +2 more
- Anchorage, Alaska
- +155 more
2022-04-06
Apr 6, 2022I
Active, not recruiting
- Lymphoma
- Parsaclisib
- Phoenix, Arizona
- +82 more
2022-01-14
Jan 14, 2022I
Recruiting
- Myelofibrosis
- +3 more
- parsaclisib
- +2 more
- Berkeley, California
- +178 more
2022-03-22
Mar 22, 2022I
Completed
- Lymphoma
- Parsaclisib
- Birmingham, Alabama
- +69 more
2022-02-28
Feb 28, 2022